The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
NEUTRALIZATION:To yield one-half maximal inhibition [ND50] of the biological activity of rMCP-4 (100ng/ml), a concentration of 1-5µg/ml of the antibody is required.
ELISA:This antibody can be used at a concentration of 1-2µg/ml, as a capture antibody in conjunction with a compatible secondary reagent to yield satisfactory results in a sandwich ELISA (using 100µl/well antibody solution).
Chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. Signals through CCR2B and CCR3 receptors. Plays a role in the accumulation of leukocytes at both sides of allergic and non-allergic inflammation. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. May play a role in the monocyte attraction in tissues chronically exposed to exogenous pathogens.
Widely expressed. Found in small intestine, thymus, colon, lung, trachea, stomach and lymph node. Low levels seen in the pulmonary artery smooth muscle cells.
Belongs to the intercrine beta (chemokine CC) family.
One major form (form long), and two minor forms (short chain and medium chain) are produced by differential signal peptide cleavage. The medium chain is about 30-fold less active than the long chain.
Small inducible cytokine subfamily A (Cys Cys) member 13 antibody
Small-inducible cytokine A13 antibody
This product has been referenced in:
Martin P et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol179:422-35 (2011).
Read more (PubMed: 21703421) »